High Tide Featured at AltaCorp – ATB 7th Annual Institutional Investor Conference, Lift & Co. Cannabis Expo and Benzinga Cannabis Capital Conference

High Tide Inc. (CSE:HITI) today announced that senior executives of the Company are featured speakers at the AltaCorp – ATB 7th Annual Institutional Investor Conference in Toronto, Ontario from January 8-10, 2019 (“AltaCorp Conference”), at the Lift & Co. Cannabis Expo Industry Day in Vancouver, British Columbia on Thursday, January 10, 2019 (“Lift & Co. Expo”) and at the Benzinga Cannabis Capital Conference in Miami, Florida from January 15-16, 2019 (“Benzinga Conference”). 

Engagement Labs Analytics About Value of Consumer Conversations Published in MIT Sloan Management Review

NEW YORK, Jan. 10, 2019 /PRNewswire/ — Engagement Labs Inc. (TSXV: EL) (OTCQB: ELBSF), an industry-leading data and analytics firm that provides social intelligence for Fortune 500 companies, announces that a new analysis by the Company is published in MIT Sloan Management Review.

High Hampton subsidiary 420 Realty receives six licenses from the State of California

TORONTO, Jan. 10, 2019 /CNW/ – High Hampton Holdings Corp. (CSE: HC) (FSE: 0HCN) (“High Hampton” or the “Company”) is pleased to announce that its wholly owned subsidiary 420 Realty LLC (“420 Realty”) has received six California State cannabis licenses to operate at its facility located in the City of Cudahy.

Snipp Announces Q4, 2018 as the Largest Quarter of Sales Booking in Company History With Sales of $4.5MM

TORONTO, Jan. 08, 2019 (GLOBE NEWSWIRE) — Snipp Interactive Inc. (“Snipp” or the “Company”) (OTCQB: SNIPF; TSX-V: SPN), a global provider of digital marketing promotions, rebates and loyalty solutions, today announced that it achieved US$4.5MM in sales bookings in the recently concluded 4th Quarter of 2018, the largest quarterly bookings in company history. In terms of annual bookings, 2018 was also a record year for Snipp in other categories, as the Company exceeded US$15MM in annual sales bookings for the first time ever and set a new record for number of programs sold at over 320 with a bookings margin of 75%.

FSD Pharma Completes Harvest and Passes Analytical Testing of Second Lot

TORONTO, Jan. 8, 2019 /CNW/ – FSD Pharma Inc. (“FSD Pharma” or the “Company”) (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) is pleased to announce that its wholly-owned subsidiary, FV Pharma Inc. (“FV Pharma”), a licensed cannabis producer under the Cannabis Act, has completed the harvest of its second lot of cannabis and successfully passed all analytical testing, thereby positioning the Company to request a Pre-Sales License Inspection from Health Canada. The Pre-Sales License Inspection is the last step prior to the issuance of a Sales License under the Cannabis Act and Regulations.

Enthusiast Gaming to Acquire “The Sims Resource”, The World’s Largest Female Video Gaming Website

TORONTO, ONTARIO, January 7, 2019– Enthusiast Gaming Holdings Inc. (“Enthusiast” or the “Company”) (TSXV: EGLX), is pleased to announce that it has, through a wholly-owned subsidiary, signed a definitive agreement on January 3, 2019 (the “Agreement“) for the Company to acquire 100% of the assets of The Sims Resource (“TSR”) from Generatorhallen AB and IBIBI HB (the “Vendors”) on an arm’s length basis for US$18 million in cash and US$2 million in stock for an aggregate purchase price of US$20 million (the “Purchase Price“). Thirty percent (30%) of the Purchase Price is payable on closing and the balance payable by the first anniversary date of closing, subject to certain customary adjustments (the “Transaction“). Completion of the Transaction is subject to

Continue Reading “Enthusiast Gaming to Acquire “The Sims Resource”, The World’s Largest Female Video Gaming Website”

NuRAN Wireless Announces Proposed Amendment To Its Senior Secured Debentures

NuRAN Wireless Inc. (CSE:NUR) (OTC:NRRWF) (FSE:1RN) (the “Company” or “NuRAN”) wishes to announce that it has made an offer to holders of its previously issued 12% Senior Secured Convertible Debentures (the “Debentures”) to fix the conversion price of the Debentures at $0.10 per common share (the Debentures are currently convertible at $0.12 per common share) and remove any adjustment provisions relating to future financings completed at a price lower than the conversion price (the “Debenture Amendment”).

Nutritional High Enters Into Asset Purchase Agreement in Washington

TORONTO, Jan. 03, 2019 (GLOBE NEWSWIRE) — Nutritional High International (“Nutritional High” or the “Company”) (CSE: EAT, OTCQB: SPLIF, FRANKFURT:2NU) is pleased to announce that it has entered into an Asset Purchase Agreement (the “Agreement”), as amended on December 26, 2018, between its wholly-owned Nevada subsidiary (the “Subsidiary”), and a Washington limited liability company (the “Seller”), pursuant to which the Subsidiary will acquire assets and certain IP brands from the Seller.

Nuvo Pharmaceuticals Announces Appointment of Rob Harris as Executive Chairman

MISSISSAUGA, ON, Jan. 3, 2019 /PRNewswire/ – Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX: NRI; OTCQX : NRIFF), a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products, today announced the appointment of Rob Harris as its Executive Chairman. Mr. Harris joined Nuvo’s board of directors in May 2017 and was previously the co-founder and Chief Executive Officer of Tribute Pharmaceuticals Inc. (Tribute), formerly a Toronto Stock Exchange listed company. Tribute was purchased in 2016 by Aralez Pharmaceuticals Inc., renamed Aralez Canada Inc. and then purchased by Nuvo in a transaction that was completed December 31, 2018. Mr. Harris assumes the Executive Chairman role from John London who will become the Company’s non-executive Vice-Chairman.

Continue Reading “Nuvo Pharmaceuticals Announces Appointment of Rob Harris as Executive Chairman”

FSD Pharma Responds to Therapix Termination of Binding LOI

FSD Pharma Inc. (“FSD Pharma” or “FSD”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) in response to Therapix Biosciences’ termination of the company’s binding letter of intent (LOI) to be acquired by FSD Pharma, Dr. Raza Bokhari, Executive Co-Chairman of the Board of FSD Pharma, released the following statement: